Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3281314 | 0.74 | PKM (0.41) | TSHR | |
| SCHEMBL8994002 | 0.68 | ESR1 (0.36) | TSHR | |
| SCHEMBL5644305 | 0.68 | KDM4E (0.34) | TSHR | |
| SCHEMBL24378472 | 0.68 | MAPT (0.37) | TSHR | |
| SCHEMBL29333799 | 0.68 | HASPIN (0.34) | TSHR | |
| SCHEMBL743560 | 0.65 | — | — | |
| SCHEMBL5610053 | 0.64 | TSHR (0.31) | TSHR | |
| SCHEMBL24378525 | 0.64 | ALDH1A1 (0.39) | — | |
| SCHEMBL755197 | 0.62 | — | — | |
| SCHEMBL666356 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199139-B2 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2007-04-03 | — | — | US | disclosed |
| EP-1354602-B1 | MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT | SANKYO CO (JP) | 2006-10-04 | — | — | EP | disclosed |
| EP-1695716-A2 | Medicinal compositions containing diuretics and insulin sensitizers | Sankyo Company, Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-20050288339-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2005-12-29 | — | — | US | disclosed |
| US-20040053974-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| US-20040006141-A1 | Amidocarboxylic acid compounds | SANKYO COMPANY, LTD (JP) | 2004-01-08 | — | — | US | disclosed |
| EP-1354602-A1 | MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT | Sankyo Company, Limited (JP) | 2003-10-22 | — | — | EP | disclosed |
| EP-0916651-B1 | PHENYLALKYLCARBOXYLIC ACID DERIVATIVES | SANKYO CO (JP) | 2003-10-15 | — | — | EP | disclosed |
| US-6528525-B1 | Amidocarboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-03-04 | — | — | US | disclosed |
| US-6103907-A | ALDOSE REDUCTASE INHIBITING ANTIDIABETIC AGENT | SANKYO COMPANY, LIMITED (JP) | 2000-08-15 | — | — | US | disclosed |
| EP-1026149-A1 | AMIDOCARBOXYLIC ACID DERIVATIVES | Sankyo Company Limited (JP) | 2000-08-09 | — | — | EP | disclosed |
| US-5972959-A | Oxime derivatives, their preparation and their therapeutic use | SANKYO COMPANY, LIMITED (JP) | 1999-10-26 | — | — | US | disclosed |
| CN-1219927-A | Phenylalkylcarboxylic acid derivatives | SANKYO CO (JP) | 1999-06-16 | — | — | CN | disclosed |
| EP-0916651-A1 | PHENYLALKYLCARBOXYLIC ACID DERIVATIVES | Sankyo Company, Limited (JP) | 1999-05-19 | — | — | EP | disclosed |
| EP-0708098-B1 | Oxime derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 1999-03-03 | — | — | EP | disclosed |
| US-5780490-A | A O-(2,4-OXA(OR THIA)ZOLIDINYL)PHENYLOXY(OR THIO OR AMINO) ALKYLOXIME; ALDOSE REDUCTASE INHIBITORS; ANTIDIABETIC AND -HYPOGLYCEMIC AGENTS; LIVER, SKIN AND UROGENITAL DISORDERS | SANKYO COMPANY, LIMITED (JP) | 1998-07-14 | — | — | US | disclosed |
| US-5703096-A | ANTIDIABETIC AGENTS; ALDOSE REDUCTASE INHIBITOR | SANKYO COMPANY, LIMITED (JP) | 1997-12-30 | — | — | US | disclosed |
| EP-0708098-A1 | Oxime derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1996-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053974-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | GPR119, INSR, IRS1 | TSHR 899/4885 |
| US-20040006141-A1 | Amidocarboxylic acid compounds | NR1H2, AGK, APOL1 | TSHR 257/4885 |
| US-20050288339-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | GPR119, INSR, IRS1 | TSHR 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.